|
Thrombocytopenia
|
0.310 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
In conclusion, IKZF5 is a novel transcriptional regulator of megakaryopoiesis and the eighth transcription factor associated with dominant thrombocytopenia in humans.
|
31217188 |
2019 |
|
Thrombocytopenia
|
0.310 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, IKZF5 is a novel transcriptional regulator of megakaryopoiesis and the eighth transcription factor associated with dominant thrombocytopenia in humans.
|
31217188 |
2019 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension.
|
21082022 |
2010 |
|
Myocardial Infarction
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
|
31218354 |
2019 |
|
Myocardial Infarction
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Patients with a history of MI 1 to 3 years before inclusion in the PEGASUS-TIMI 54 trial were stratified in a pre-specified analysis based on the presence of MVD.
|
29406853 |
2018 |
|
Myocardial Infarction
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.
|
30571502 |
2018 |
|
Myocardial Infarction
|
0.070 |
Biomarker
|
disease |
BEFREE |
Approval is based on the results of the PEGASUS-TIMI 54 trial that compared ticagrelor with placebo (in conjunction with low-dose aspirin) in stable patients who had had a spontaneous MI 1-3 years prior to enrolment and were at high risk of atherothrombotic events.
|
29150806 |
2017 |
|
Myocardial Infarction
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The authors performed a prospective economic substudy alongside the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA.
|
28750695 |
2017 |
|
Myocardial Infarction
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Long-term use of ticagrelor in patients with previous myocardial infarction (MI) has been investigated in the PEGASUS-TIMI-54 trial.
|
28097533 |
2017 |
|
Myocardial Infarction
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
(Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).
|
28882235 |
2017 |
|
Cerebrovascular accident
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Background Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS-TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin).
|
30571502 |
2018 |
|
Cerebrovascular accident
|
0.030 |
Biomarker
|
group |
BEFREE |
(Prevention of Cardiovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).
|
29406853 |
2018 |
|
Cerebrovascular accident
|
0.030 |
Biomarker
|
group |
BEFREE |
(Prevention of Cardiovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).
|
28750695 |
2017 |
|
Malignant neoplasm of prostate
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We perform fine-mapping of PCa risk across TET2 using genotypes from the PEGASUS case-control cohort and identify six new risk variants in introns 1 and 2.
|
27819678 |
2017 |
|
Prostate carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We perform fine-mapping of PCa risk across TET2 using genotypes from the PEGASUS case-control cohort and identify six new risk variants in introns 1 and 2.
|
27819678 |
2017 |
|
Malignant neoplasm of prostate
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A genome-wide association study (GWAS) of prostate cancer in Kaiser Permanente health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0% East Asian, and 7.8% Latino) revealed a new independent risk indel rs4646284 at the previously identified locus 6q25.3 that replicated in PEGASUS (N = 7,539) and the Multiethnic Cohort (N = 4,679) with an overall P = 1.0 × 10(-19) (OR, 1.18).
|
26034056 |
2015 |
|
Prostate carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A genome-wide association study (GWAS) of prostate cancer in Kaiser Permanente health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0% East Asian, and 7.8% Latino) revealed a new independent risk indel rs4646284 at the previously identified locus 6q25.3 that replicated in PEGASUS (N = 7,539) and the Multiethnic Cohort (N = 4,679) with an overall P = 1.0 × 10(-19) (OR, 1.18).
|
26034056 |
2015 |
|
Acute myocardial infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We aimed to elaborate a risk score, based on the PEGASUS-TIMI 54 criteria, to predict mortality and non-fatal AMI in AMI patients.
|
30528624 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine whether ticagrelor 60 mg twice daily (bid) provided potent and consistent platelet inhibition in patients with vs without diabetes in the PEGASUS-TIMI 54 platelet function substudy.
|
28300867 |
2017 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
This study aimed to determine whether ticagrelor 60 mg twice daily (bid) provided potent and consistent platelet inhibition in patients with vs without diabetes in the PEGASUS-TIMI 54 platelet function substudy.
|
28300867 |
2017 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then used PEGASUS gene scores as input to the network analysis algorithm HotNet2 to characterize the genomic architecture of ALL.<b>Results:</b> Using PEGASUS, we confirmed associations previously observed at genes such as <i>ARID5B, IKZF1, CDKN2A/2B</i>, and <i>PIP4K2A</i>, and we identified novel candidate gene associations.
|
28751478 |
2017 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then used PEGASUS gene scores as input to the network analysis algorithm HotNet2 to characterize the genomic architecture of ALL.<b>Results:</b> Using PEGASUS, we confirmed associations previously observed at genes such as <i>ARID5B, IKZF1, CDKN2A/2B</i>, and <i>PIP4K2A</i>, and we identified novel candidate gene associations.
|
28751478 |
2017 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then used PEGASUS gene scores as input to the network analysis algorithm HotNet2 to characterize the genomic architecture of ALL.<b>Results:</b> Using PEGASUS, we confirmed associations previously observed at genes such as <i>ARID5B, IKZF1, CDKN2A/2B</i>, and <i>PIP4K2A</i>, and we identified novel candidate gene associations.
|
28751478 |
2017 |